1-Propyl-3-methylpyrrol | 10524-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-Propyl-3-methylpyrrol
• 英文别名: N-Propyl-3-methyl-pyrrol；3-Methyl-N-propylpyrrol；3-methyl-1-propyl-pyrrole；3-Methyl-1-propylpyrrole
• CAS: 10524-66-0
• 化学式: C₈H₁₃N
• 分子量: 123.198
• InChiKey: XDAQQJSUBMBOHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS<br/>[FR] HYDANTOÏNE CONTENANT DES INHIBITEURS DE LA DÉSOXYURIDINE TRIPHOSPHATASE
  申请人：CV6 THERAPEUTICS NI LTD

  公开号：WO2018098206A1

  公开（公告）日：2018-05-31

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

  提供的是dUTPase抑制剂，包含此类化合物的组合物以及使用此类化合物和组合物的方法。
• PHARMACEUTICAL COMPOSITION COMPRISING AROMATIC HETEROCYCLIC COMPOUND
  申请人：Takada Chie

  公开号：US20120196854A1

  公开（公告）日：2012-08-02

  A pharmaceutical composition comprising as an active ingredient, an aromatic heterocyclic compound represented by the formula (I): [wherein Q 1 represents CR 2 (wherein R 2 represents a hydrogen atom or the like) or the like; Q 2 represents CR 3 (wherein R 3 represents a hydrogen atom or the like) or the like; Q 3 represents a nitrogen atom or the like; R 1 represents —C(═O)OR 16 (wherein R 16 represents a hydrogen atom or the like) or the like; R 5 represents a hydrogen atom or the like; R 6 represents optionally substituted cycloalkyl or the like; X and Y may be the same or different and each represent CH in which H may be substituted with a substituent or the like; and Z represents a nitrogen atom or the like] or the like is provided.

  提供一种药物组合物，其活性成分为一种芳香杂环化合物，其化学式为（I）：[其中Q1代表CR2（其中R2代表氢原子或类似物）或类似物；Q2代表CR3（其中R3代表氢原子或类似物）或类似物；Q3代表氮原子或类似物；R1代表—C(═O)OR16（其中R16代表氢原子或类似物）或类似物；R5代表氢原子或类似物；R6代表可选择取代的环烷基或类似物；X和Y可以相同也可以不同，并且每个代表CH，其中H可以被取代为取代基或类似物；Z代表氮原子或类似物]或类似物。
• Raf Kinase Inhibitors
  申请人：WOOD Jill E.

  公开号：US20100063088A1

  公开（公告）日：2010-03-11

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  使用替代尿素类化合物治疗由Raf激酶介导的肿瘤的方法，以及这些化合物本身。
• RAF KINASE INHIBITORS
  申请人：WOOD Jill E.

  公开号：US20120178780A1

  公开（公告）日：2012-07-12

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  使用取代脲类化合物治疗由raf激酶介导的肿瘤的方法，以及这些化合物本身。
• HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP3517112A1

  公开（公告）日：2019-07-31

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra', Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  所公开的化学实体为式（I）化合物： 或其药学上可接受的盐；其中 Y、Ra、Ra'、Rb、Rc、X1、X2、X3、Rd、Z1 和 Z2 具有本文所述的值，星号位置上描述的立体化学构型表示绝对立体化学。根据本公开的化学实体可用作苏木活化酶（SAE）的抑制剂。进一步提供了包含本公开化合物的药物组合物，以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或紊乱的方法。